H. Brett‐Smith

1.5k total citations
27 papers, 1.1k citations indexed

About

H. Brett‐Smith is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, H. Brett‐Smith has authored 27 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Epidemiology, 19 papers in Hepatology and 9 papers in Infectious Diseases. Recurrent topics in H. Brett‐Smith's work include Hepatitis B Virus Studies (20 papers), Hepatitis C virus research (18 papers) and Liver Disease Diagnosis and Treatment (9 papers). H. Brett‐Smith is often cited by papers focused on Hepatitis B Virus Studies (20 papers), Hepatitis C virus research (18 papers) and Liver Disease Diagnosis and Treatment (9 papers). H. Brett‐Smith collaborates with scholars based in United States, Germany and Taiwan. H. Brett‐Smith's co-authors include Robert G. Gish, You‐Chen Chao, Adrián Gadano, Ricardo Tamez, Ting‐Tsung Chang, Robert A. de Man, Katherine Staskus, Anthony J. Jaslowski, Craig E. Metroka and George Miller and has published in prestigious journals such as Gastroenterology, Hepatology and Journal of Virology.

In The Last Decade

H. Brett‐Smith

26 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. Brett‐Smith United States 17 999 819 203 189 75 27 1.1k
Marla A. Shu United States 4 475 0.5× 355 0.4× 172 0.8× 72 0.4× 34 0.5× 4 572
Laurence Héripret France 8 319 0.3× 209 0.3× 139 0.7× 274 1.4× 13 0.2× 11 597
Hugues Aumaître France 7 359 0.4× 324 0.4× 45 0.2× 88 0.5× 16 0.2× 19 497
C. J. Tibbs United Kingdom 19 523 0.5× 544 0.7× 119 0.6× 49 0.3× 15 0.2× 30 855
Vincenzo Guadagnino Italy 15 752 0.8× 822 1.0× 24 0.1× 104 0.6× 7 0.1× 42 950
C. Cornù Belgium 13 618 0.6× 633 0.8× 60 0.3× 181 1.0× 6 0.1× 38 858
Axel Baumgarten Germany 19 671 0.7× 718 0.9× 56 0.3× 571 3.0× 17 0.2× 78 1.2k
C. Vandelli Italy 10 513 0.5× 525 0.6× 34 0.2× 92 0.5× 10 0.1× 26 674
Davide Precone Italy 10 627 0.6× 535 0.7× 54 0.3× 101 0.5× 5 0.1× 13 751
Ricardo Franco United States 13 359 0.4× 377 0.5× 26 0.1× 102 0.5× 18 0.2× 43 514

Countries citing papers authored by H. Brett‐Smith

Since Specialization
Citations

This map shows the geographic impact of H. Brett‐Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Brett‐Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Brett‐Smith more than expected).

Fields of papers citing papers by H. Brett‐Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Brett‐Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Brett‐Smith. The network helps show where H. Brett‐Smith may publish in the future.

Co-authorship network of co-authors of H. Brett‐Smith

This figure shows the co-authorship network connecting the top 25 collaborators of H. Brett‐Smith. A scholar is included among the top collaborators of H. Brett‐Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Brett‐Smith. H. Brett‐Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chang, Ting‐Tsung, You‐Chen Chao, Kwang‐Hyub Han, et al.. (2009). Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B. Journal of Viral Hepatitis. 16(11). 784–789. 20 indexed citations
2.
Gish, Robert G., Ting‐Shou Chang, Ching‐Lung Lai, et al.. (2009). Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B*. Journal of Viral Hepatitis. 17(1). 16–22. 109 indexed citations
3.
Pessôa, Mário Guimarães, Brian Gazzard, Carlos Eduardo Brandão‐Mello, et al.. (2008). Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS. 22(14). 1779–1787. 33 indexed citations
4.
Schiff, Eugene R., Halis Şimşek, William M. Lee, et al.. (2008). Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic Fibrosis or Cirrhosis. The American Journal of Gastroenterology. 103(11). 2776–2783. 92 indexed citations
5.
Shouval, Daniel, Ching‐Lung Lai, Ting‐Tsung Chang, et al.. (2008). Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy. Journal of Hepatology. 50(2). 289–295. 83 indexed citations
6.
Chang, Ting‐Tsung, You‐Chen Chao, Ching‐Lung Lai, et al.. (2008). Four-Year Treatment with Entecavir Results in High Proportions of Nucleoside-Naïve HBeAg-Positive Patients with Undetectable HBV DNA: Results from Studies ETV-022 and -901. 1 indexed citations
7.
Han, Steven, Ting‐Tsung Chang, You‐Chen Chao, et al.. (2008). Four-Year Entecavir Treatment in Nucleoside-Naïve HBeAg(+) Patients: Results from Studies ETV-022 and -901. Hepatology. 46(9). 11 indexed citations
8.
Rose, R.E., et al.. (2008). Entecavir at Five Years Shows Long-Term Maintenance of High Genetic Barrier to Hepatitis B Virus Resistance. Zeitschrift für Gastroenterologie. 46(9). 45 indexed citations
9.
Gish, Robert G., Anna S. Lok, Ting‐Tsung Chang, et al.. (2007). Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B. Gastroenterology. 133(5). 1437–1444. 284 indexed citations
10.
11.
Chang, Ting‐Tsung, You‐Chen Chao, Sabahattin Kaymakoğlu, et al.. (2006). ENTECAVIR MAINTAINED VIROLOGIC SUPPRESSION THROUGH 3 YEARS OF TREATMENT IN ANTIVIRALNAı‥VE HBEAG PATIENTS (ETV 022/901). 19 indexed citations
12.
Man, Robert A. de, David Mutimer, Robert G. Gish, et al.. (2006). P.090 Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022). Journal of Clinical Virology. 36. S89–S89. 20 indexed citations
13.
14.
Poordad, F., Daniel Shouval, Ching‐Lung Lai, et al.. (2006). Continued Virologic Improvement Through 96 Weeks of Entecavir Treatment in HBeAg(-) Chronic Hepatitis B Patients (Study ETV-027). 5 indexed citations
15.
Selwyn, Peter A., Joseph L. Goulet, Susan Molde, et al.. (2000). HIV as a chronic disease: Implications for long-term care at an AIDS-dedicated skilled nursing facility. Journal of Urban Health. 77(2). 187–203. 27 indexed citations
16.
Staskus, Katherine, Ren Sun, George Miller, et al.. (1999). Cellular Tropism and Viral Interleukin-6 Expression Distinguish Human Herpesvirus 8 Involvement in Kaposi’s Sarcoma, Primary Effusion Lymphoma, and Multicentric Castleman’s Disease. Journal of Virology. 73(5). 4181–4187. 202 indexed citations
17.
Lee, L., Baohua Wu, H. Brett‐Smith, & Paul Fiedler. (1998). Human immunodeficiency virus-related progressive multifocal leukoencephalopathy with a CD4+ of 444 per mm3: a case report.. PubMed. 62(10). 579–82.
18.
Waxman, Aaron B., et al.. (1997). Cytomegalovirus as a Primary Pulmonary Pathogen in AIDS. CHEST Journal. 111(1). 128–134. 34 indexed citations
19.
20.
Brett‐Smith, H., et al.. (1990). Treatment of Encainide Proarrhythmia with Hypertonic Saline. Pacing and Clinical Electrophysiology. 13(10). 1232–1235. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marla A. Shu Breakdown of academic impact, for papers by Laurence Héripret Breakdown of academic impact, for papers by Hugues Aumaître Breakdown of academic impact, for papers by C. J. Tibbs Breakdown of academic impact, for papers by Vincenzo Guadagnino Breakdown of academic impact, for papers by C. Cornù Breakdown of academic impact, for papers by Axel Baumgarten Breakdown of academic impact, for papers by C. Vandelli Breakdown of academic impact, for papers by Davide Precone Breakdown of academic impact, for papers by Ricardo Franco
Rankless by CCL
2026